Background: Non-invasive prenatal testing (NIPT) has been established as a routine prenatal screening to assess the risk of common foetal aneuploidy disorder (trisomy 21, 18, and 13). NIPT has high sensitivity and high specificity, but false positive and false negative results still exist. False negative NIPT results involving Down syndrome are rare, but have a high clinical impact on families and society.

Case Presentation: We described a case of a foetus that tested "negative" for trisomy 21 (Z-score was 0.664) by NIPT based on the semiconductor sequencing platform (SSP). The foetal fraction of cell-free DNA was 16.9%; this percentage was much larger than the threshold of 4% for obtaining accurate NIPT results. However, postnatally, the newborn was diagnosed with Down syndrome with the 46,XY,der(21;21)(q10;q10),+ 21 karyotype.

Conclusions: We presented a case of false negative NIPT results, which may occur through biological mechanisms rather than poor quality, technical errors or negligence. It is imperative for clinical geneticists and their patients to understand that NIPT is still a screening test.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339513PMC
http://dx.doi.org/10.1186/s12920-020-00751-8DOI Listing

Publication Analysis

Top Keywords

false negative
16
non-invasive prenatal
8
prenatal testing
8
negative nipt
8
nipt
7
false
5
rare syndrome
4
syndrome foetus
4
foetus novo
4
novo 21q21q
4

Similar Publications

Despite its low incidence in Europe, rubella's immune status is still routinely assessed using commercial immunoassays. However, some discrepancies have been observed between these tests and the Immunoblot. The main objective of this study is to evaluate, by a commercial immunoblot, the immune status of a female population that had previously presented negative, low-positive, or equivocal rubella IgG with a commercial immunoassay.

View Article and Find Full Text PDF

Purpose: Mortality and morbidity of patients with bloodstream infection (BSI) remain high despite advances in diagnostic methods and efforts to speed up reporting. This study investigated the impact of reporting rapid Minimum Inhibitory Concentration (MIC)-results in Gram negative BSIs with the ASTar system (Q-linea, Uppsala, Sweden) on the adaptation of empirically started antimicrobial therapy. We performed a real-world study during which antimicrobial susceptibility testing (AST) results were instantly reported to the treating physician in an established multidisciplinary antimicrobial stewardship setting.

View Article and Find Full Text PDF

Reusable Biosensor for Easy RNA Detection from Unfiltered Saliva.

Sensors (Basel)

January 2025

Department of Clinical and Molecular Biochemistry, Pomeranian Medical University in Szczecin, 72 Powstańców Wlkp. Al., 70-111 Szczecin, Poland.

Biosensors are transforming point-of-care diagnostics by simplifying the detection process and enabling rapid, accurate testing. This study introduces a novel, reusable biosensor designed for direct viral RNA detection from unfiltered saliva, targeting SARS-CoV-2. Unlike conventional methods requiring filtration, our biosensor leverages a unique electrode design that prevents interference from saliva debris, allowing precise measurements.

View Article and Find Full Text PDF

: Chronic obstructive pulmonary disease (COPD) is a frequent but underdiagnosed disease, primarily due to the lack of access to forced spirometry (FS) in primary care. Portable, easy-to-use expiratory flow meters like Piko-6 and COPD-6 that measure FEV, FEV, and FEV/FEV ratio provide an alternative. Given that Piko-6 and COPD-6 devices measure FEV but not FVC, the aim of the study is to determine the optimal cutoff value for the FEV/FEV ratio of each device to avoid false negatives when these devices are used for COPD screening in primary care (PC).

View Article and Find Full Text PDF

The human leukocyte antigen (HLA) system plays a critical role in transplant immunology, influencing outcomes through various immune-mediated rejection mechanisms. Hyperacute rejection is driven by preformed donor-specific antibodies (DSAs) targeting HLAs, leading to complement activation and graft loss within hours to days. Acute rejection typically occurs within six months post-transplantation, involving cellular and humoral responses, including the formation of de novo DSAs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!